Note: Live price is not available for this stock. Showing closing price. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
SYNCOMF Stock Analysis
Views
Red Flags
Positive
Stock is reasonably valued and PE TTM is at a discount to industry median
High and improving ROE
Strong revenue growth and above median growth of industry
Strong EPS growth and above median growth of industry
Low Debt to Equity, not much change from last year
Company is net cash
Negative
Weak price momentum
Low dividend yield
Neutral
Moderate and stable operating margin
Company's earnings are of moderate quality
No red flags found!
No significant red flags found in the stock.
Snapshot
See detailed analysis
SYNCOMF Shareholding Pattern
An overview of who owns the company. Click on chart icon to view historical movement.
SYNCOMF Bulk, Block & Insider Trades
SYNCOMF Dividends, Splits & Bonus
Dividend Events
Capital Change Events
Bonus
Rights issue
Stock split
Bonus(5 new shares for 2 existing shares)AGM 05 August 2013. Ex-date: 19th Aug 2013 Announced on: 8th Jul 2013
Rights issue(1 new shares @ 17 INR for 2 existing shares)Rights issue of 3112500 Equity shares and issue of 1 detachable warrant for every 1 equity share allotted on right basis. Ex-date: 13th May 2009 Announced on: 11th Nov 2008
Stock split(1 : 10)AGM 05 August 2013. Nominal value change from INR 10 to INR 1. Ex-date: 19th Aug 2013 Announced on: 8th Jul 2013
Company Profile
Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the development, manufacturing & sale of pharmaceutical products and services& trading of commodities and renting of properties. The Company manufactures and market... Read More
Key personnel
Mr. Ankit BankdaD
Whole Time Chairman of the Board
Shri. Rahul Vijay Bankda
Chief Financial Officer
Ms. Vaishali Agrawal
Compliance Officer, Company Secretary
Shri. Vijay Shankarlal BankdaD
Managing Director, Executive Director
Shri. Kedarmal Shankarlal BankdaD
Whole-Time Director
Smt. Ruchi JindalD
Additional Woman Independent Director
Mr. Ankit JainD
Additional Non-Executive Independent Director
Mr. Ritesh Kumar LunkadD
Additional Non-Executive Independent Director
Incorporated on
Last Annual
Last Interim
No. of Employees
IPO date
Free Float
Website
Phone no.
Address
Frequently asked questions
What is the current share price of Syncom Formulations (India) Ltd.?
The current share price of Syncom Formulations (India) Ltd. is ₹ 13.13 as of 09 Jan 2026.
What is the PE ratio of Syncom Formulations (India) Ltd.?
The Price-to-Earnings (PE) ratio of Syncom Formulations (India) Ltd. is 21.44 as of the latest financial data.
What is the ROE and ROCE of Syncom Formulations (India) Ltd.?
Syncom Formulations (India) Ltd. has a Return on Equity (ROE) of 16.63% and a Return on Capital Employed (ROCE) of 13.84% as per the latest financial reports.
What is the market cap of Syncom Formulations (India) Ltd.?
The market capitalization of Syncom Formulations (India) Ltd. stands at ₹ 1,234.22 Cr.
What is the dividend yield of Syncom Formulations (India) Ltd.?
The dividend yield of Syncom Formulations (India) Ltd. is 0.00% based on the current market price.
What is the RSI of Syncom Formulations (India) Ltd.?
The Relative Strength Index (RSI) of Syncom Formulations (India) Ltd. is 25.92.
What is the FII and DII holding in Syncom Formulations (India) Ltd.?
Foreign Institutional Investors (FII) hold 0.26% and Domestic Institutional Investors (DII) hold 0.00% of Syncom Formulations (India) Ltd. shares.
What sector does Syncom Formulations (India) Ltd. belong to?
Syncom Formulations (India) Ltd. operates in the Healthcare sector.
What is the beta of Syncom Formulations (India) Ltd. stock?
The beta of Syncom Formulations (India) Ltd. stock is 1.34, indicating its volatility relative to the broader market.
